Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
Mural Oncology plc (Nasdaq: MURA) has announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20, 2024. Minegishi will serve as Chair of the Audit Committee and join the Nominating and Corporate Governance Committee. With over 20 years of industry experience, she brings expertise in corporate strategy, finance, development, and commercialization.
Currently the Chief Operating Officer at Rectify Pharmaceuticals, Minegishi has previously held leadership roles at Akouos, bluebird bio, Human Genome Sciences, Genzyme, and Amgen. Her appointment comes as Mural Oncology prepares for key milestones, including candidate nominations for IL-18 and IL-12 programs this year and readouts in two potentially registrational studies of nemvaleukin in the first half of 2025.
Mural Oncology plc (Nasdaq: MURA) ha annunciato la nomina di Sachiyo Minegishi nel suo consiglio di amministrazione, a partire dal 20 settembre 2024. Minegishi assumerà il ruolo di Presidente del Comitato di Revisione e entrerà a far parte del Comitato per le Nomine e la Governance Aziendale. Con oltre 20 anni di esperienza nel settore, porta con sé competenze in strategia aziendale, finanza, sviluppo e commercializzazione.
Attualmente Chief Operating Officer di Rectify Pharmaceuticals, Minegishi ha ricoperto in precedenza ruoli di leadership in Akouos, bluebird bio, Human Genome Sciences, Genzyme e Amgen. La sua nomina avviene mentre Mural Oncology si prepara a importanti traguardi, tra cui le nomine dei candidati per i programmi IL-18 e IL-12 quest'anno e i risultati di due studi potenzialmente registrabili di nemvaleukin nella prima metà del 2025.
Mural Oncology plc (Nasdaq: MURA) ha anunciado el nombramiento de Sachiyo Minegishi en su junta directiva, que será efectivo a partir del 20 de septiembre de 2024. Minegishi se desempeñará como Presidenta del Comité de Auditoría y se unirá al Comité de Nominaciones y Gobernanza Corporativa. Con más de 20 años de experiencia en la industria, aporta experiencia en estrategia corporativa, finanzas, desarrollo y comercialización.
Actualmente, es la Directora de Operaciones de Rectify Pharmaceuticals, Minegishi ha ocupado roles de liderazgo en Akouos, bluebird bio, Human Genome Sciences, Genzyme y Amgen. Su nombramiento llega mientras Mural Oncology se prepara para hitos clave, incluyendo nominaciones de candidatos para los programas IL-18 e IL-12 este año y resultados en dos estudios potencialmente registrables de nemvaleukin en la primera mitad de 2025.
Mural Oncology plc (Nasdaq: MURA)는 사치요 미네기시를 이사회에 임명했다고 발표했으며, 이는 2024년 9월 20일부터 효력이 발생합니다. 미네기시는 감사위원회 의장으로 활동하며, 추천 및 기업 거버넌스 위원회에 합류할 것입니다. 20년 이상의 산업 경험을 가진 그녀는 기업 전략, 재무, 개발 및 상용화에 대한 전문성을 가지고 있습니다.
현재 Rectify Pharmaceuticals의 최고 운영 책임자(COO)인 미네기시는 이전에 Akouos, bluebird bio, Human Genome Sciences, Genzyme 및 Amgen에서 리더십 역할을 수행했습니다. 그녀의 임명은 Mural Oncology가 IL-18 및 IL-12 프로그램의 후보 지명을 올해 진행하고 2025년 상반기에 nemvaleukin의 두 개의 잠재적 등록 연구 결과를 준비하면서 이루어졌습니다.
Mural Oncology plc (Nasdaq: MURA) a annoncé la nomination de Sachiyo Minegishi à son conseil d'administration, effective à partir du 20 septembre 2024. Minegishi sera présidente du comité d'audit et rejoindra le comité des nominations et de la gouvernance d'entreprise. Forte de plus de 20 ans d'expérience dans l'industrie, elle apporte son expertise en stratégie d'entreprise, finance, développement et commercialisation.
Actuellement directrice des opérations chez Rectify Pharmaceuticals, Minegishi a précédemment occupé des postes de direction chez Akouos, bluebird bio, Human Genome Sciences, Genzyme et Amgen. Sa nomination intervient alors que Mural Oncology se prépare à des étapes clés, notamment les nominations de candidats pour les programmes IL-18 et IL-12 cette année et les résultats de deux études potentiellement enregistrables sur le nemvaleukin dans la première moitié de 2025.
Mural Oncology plc (Nasdaq: MURA) hat die Ernennung von Sachiyo Minegishi in seinen Vorstand bekanntgegeben, die am 20. September 2024 wirksam wird. Minegishi wird den Vorsitz des Prüfungsausschusses übernehmen und dem Nominierungs- und Corporate Governance-Ausschuss beitreten. Mit über 20 Jahren Branchenerfahrung bringt sie Fachwissen in den Bereichen Unternehmensstrategie, Finanzen, Entwicklung und Kommerzialisierung ein.
Derzeit ist sie Chief Operating Officer bei Rectify Pharmaceuticals und hat zuvor Führungspositionen bei Akouos, bluebird bio, Human Genome Sciences, Genzyme und Amgen innegehabt. Ihre Ernennung erfolgt, während sich Mural Oncology auf wichtige Meilensteine vorbereitet, einschließlich Kandidatennominierungen für die Programme IL-18 und IL-12 in diesem Jahr und Ergebnissen aus zwei potenziell registrierungsrelevanten Studien zu nemvaleukin in der ersten Hälfte von 2025.
- Appointment of experienced industry professional Sachiyo Minegishi to the board of directors
- Upcoming candidate nominations for IL-18 and IL-12 programs in 2024
- Key readouts expected in two potentially registrational studies of nemvaleukin in H1 2025
- None.
WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company’s Nominating and Corporate Governance Committee.
“With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate milestones,” said Caroline Loew, Ph.D., CEO of Mural Oncology. “Her diverse expertise will be invaluable as we look to propel Mural through the next stage of growth, with several key milestones including candidate nominations for our IL-18 and IL-12 programs this year and key readouts in our two potentially registrational studies of nemvaleukin in the first half of 2025.”
Sachiyo brings over two decades of biopharma experience, with a focus on corporate strategy, finance, development, and commercialization. She is currently the Chief Operating Officer at Rectify Pharmaceuticals, driving corporate and financing strategy to advance its lead program from discovery to clinical stage. Prior to Rectify, Sachiyo was Chief Financial Officer at Akouos, Inc., where she led corporate finance and business development strategy and played a key role in the acquisition of the company by Eli Lilly. Before that, she was a Global Program Lead at bluebird bio, where she led a team to execute global development and commercialization strategy for a portfolio of gene therapies for sickle cell disease. Sachiyo has also held leadership roles that helped accelerate corporate growth at Human Genome Sciences, Genzyme, and Amgen.
“Mural is entering an exciting time of growth, as it leverages its unique protein engineering skills to develop novel and highly differentiated immunotherapies for patients with high unmet need,” said Sachiyo. “I look forward to contributing my corporate and financing strategy expertise to help position the company for potential commercialization of its lead program and advancement of its early-stage pipeline to the clinic.”
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential, and reach, of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer reading out in the first half of 2025. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the company’s pipeline and development programs, including the expected timing of clinical updates from the ARTISTRY-6 and ARTISTRY-7 trials, the expected timing of preclinical updates and candidate selection, including with respect to the company’s IL-12 and IL-18 programs, the potential of the company’s product candidates and programs to address unmet medical needs, and the continued progress of its pipeline and programs. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, the inherent risks and uncertainties associated with competitive developments, preclinical development, clinical trials, recruitment of patients, product development activities and regulatory approval requirements; that preclinical or interim results and data from ongoing clinical studies of the company’s cytokine programs and product candidates may not be predictive of future or final results from such studies, results of future clinical studies or real-world results; future clinical trials or future stages of ongoing clinical trials may not be initiated or completed on time or at all; the company’s product candidates, including nemvaleukin, could be shown to be unsafe or ineffective; changes in the cost, scope and duration of development activities; the U.S. Food and Drug Administration may make adverse decisions regarding the company’s product candidates; and those other risks and uncertainties set forth in the company’s filings with the Securities and Exchange Commission (“SEC”), including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 and in subsequent filings the company may make with the SEC. All forward-looking statements contained in this press release speak only as of the date of this press release. The company anticipates that subsequent events and developments will cause its views to change. However, the company undertakes no obligation to update such forward-looking statements to reflect events that occur or circumstances that exist after the date of this press release, except as required by law.
Contact:
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
Who is the new board member appointed by Mural Oncology (MURA)?
What roles will Sachiyo Minegishi take on at Mural Oncology (MURA)?
What are the upcoming milestones for Mural Oncology (MURA) in 2024-2025?
What is Sachiyo Minegishi's current role outside of Mural Oncology (MURA)?
